Rexam eyes factory growth, despite lagging healthcare sales

Despite lagging healthcare sales for the first half of the year, hurt in part by a weak flu season in the U.S., global packaging company Rexam will expand two plants to meet increased demand. Healthcare profit fell to £27 million ($42 million) from £36 million ($49.8 million), but the British company says there's a need for insulin pens and multilayer containers, according to Manufacturing Chemist. With that growth in mind, Rexam will expand its plants in India and La Verpillière, France, to meet those needs. And while Rexam's bread and butter may lie with making beverage cans, the company says it's committed to working more directly with pharmaceutical companies to expand its healthcare offerings. Story

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.